|
epithelium |
stroma |
|||
Endometrium |
atrophic |
1/181 |
0/181 |
||
weakly proliferative |
1/151 |
0/151 |
|||
proliferative |
1/161 |
0/161 |
|||
secretory |
0/191 |
5/191 |
|||
menstrual |
0/81 |
4/81 |
|||
benign, NOS |
0/203 |
|
|||
atypical endometrial hyperplasia/intra-epithelial neoplasia |
3/351 |
|
|||
serous glandular dysplasia |
6/211 |
|
|||
serous intra-epithelial neoplasia |
|
||||
clear cell glandular dysplasia |
2/121 |
|
|||
clear cell intra-epithelial neoplasia |
6/81 |
|
|||
gestational endometrium |
0/161 |
||||
trophoblast |
|||||
endometrial carcinoma |
endometrioid |
||||
serous |
|||||
clear cell |
|
||||
mucinous |
1/81 |
|
|||
other |
7/151 |
|
|||
IMP3 positive |
|
|||||||||||||||||
Biopsy negative for dysplasia | 0/1674 | |||||||||||||||||
CIN I | biopsy | 0/874 | ||||||||||||||||
loop excision or hysterectomy | 0/214 | |||||||||||||||||
CIN II | biopsy | 0/584 | ||||||||||||||||
loop excision or hysterectomy | 1/554 | |||||||||||||||||
biopsy | 121/6654 | |||||||||||||||||
loop excision or hysterectomy | 18/1174 | |||||||||||||||||
Invasive carcinoma | 76/794 | |||||||||||||||||
In renal cell carcinoma (this study was a mix of all types), positivity for IMP3 is associated with a lower rate of disease-free survival at five years2:
Stage |
IMP3-negative |
IMP3-positive |
||
I |
98% |
44% |
||
II |
94% |
41% |
||
II |
62% |
16% |
||
Identification of type II, serous and clear cell, carcinoma of the endometrium1,3.
Identification of CIN with a high risk of progression to invasive carcinoma4.
As a prognostic marker in renal cell carcinoma2.
References
This page last revised 21.10.2011.
©SMUHT/PW Bishop